trial

Alleviating the Metabolic Side Effects of Antipsychotic Medications

NCTId NCT01567124
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Withdrawn
Enrollment 0 (actual)
Sponsored by Baker Heart and Diabetes Institute
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-05
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Moxonidine

Sponsors

Baker Heart and Diabetes InstituteLead Sponsor
The AlfredCollaborator
Monash Medical CentreCollaborator
Ballarat Health ServicesCollaborator

Investigators

3
Gavin LambertStudy Director
David BartonPrincipal Investigator
Abdul KhalidPrincipal Investigator

Sites

4 total
Ballarat, AustraliaClayton, AustraliaMelbourne, AustraliaMelbourne, Australia

Facts & assertions

3 sourced
Enrollment
0
Phase
PHASE4
Status
WITHDRAWN
relationships
The graph out of here
drug
Moxonidine
drug
lead_sponsor
Baker Heart and Diabetes Institute
company
collaborator
The Alfred
company
Monash Medical Centre
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Gavin Lambert
person
David Barton
person
Abdul Khalid
person